Gene therapy in the cardiovascular system: an update.
This update reviews the remarkable progression in several cardiovascular gene transfer domains. The first chemical gene therapy protocols to stimulate angiogenesis in ischemic myocardium are discussed and both the great expectations as well as remaining hurdle are highlighted. In experimental models of restenosis and heart failure gene therapy shows promising results. Important question regarding vector-related limitations and suboptimal in vivo delivery systems will require expeditious attention for gene therapy to become a more widely applicable option in cardiovascular diseases.
Sinnaeve
P
P
Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU-Leuven, Belgium.
Varenne
O
O
Collen
D
D
Janssens
S
S
D000818:Animals; D001161:Arteriosclerosis / Q000628:therapy; D009320:Atrial Natriuretic Factor / Q000235:genetics; D002318:Cardiovascular Diseases / Q000628:therapy*; D003327:Coronary Disease / Q000628:therapy; D016228:Endothelial Growth Factors / Q000235:genetics; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006333:Heart Failure / Q000628:therapy; D006801:Humans; D006973:Hypertension / Q000628:therapy; D008222:Lymphokines / Q000235:genetics; D051379:Mice; D018919:Neovascularization, Physiologic; D011817:Rabbits; D013482:Superoxide Dismutase / Q000235:genetics; D013927:Thrombosis / Q000628:therapy; D010959:Tissue Plasminogen Activator / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D009320:Atrial Natriuretic Factor; D013482:Superoxide Dismutase; D010959:Tissue Plasminogen Activator